April 2012
`
`Cao H, Yu R, Tao Y, Nikolic D, van Breemen RB. Development of a LC-MS-MS assay for
`cyclooxygenase inhibition. 57th ASMS Conference on Mass Spectrometry and Allied Topics.
`Philadelphia, PA. May 31-June 4, 2009.
`Powell SL, Chen S-N, Ahn S, Godecke T, Main M, Imai A, Farnsworth NR, van Breemen RB,
`Pauli GF, Bolton JL. Serotonergic screening of botanicals used for various women’s heatlth
`issues. 50th Anniversary Meeting of the American Society of Pharmacognosy. Honolulu, HI ;
`June 27-July 1, 2009.
`Chen Y, Yang J, Kondratyuk TP, Qiu X, Choi Y, Sturdy M, Pegan S, Liu Y, Wang L, Mesecar
`AD, van Breemen RB, Pezzuto JM, Fong HHS, Zhang H. New cancer chemopreventive
`kaempferol glycosides from Neocheiropteris palmatopedata. 50th Anniversary Meeting of the
`American Society of Pharmacognosy. Honolulu, HI ; June 27-July 1, 2009.
`Marler L, Rostama B, Cushman M, van Breemen R, Grubbs C, Pezzuto J. Cancer
`chemopreventive potential of novel natural product derivatives. 50th Anniversary Meeting of the
`American Society of Pharmacognosy. Honolulu, HI ; June 27-July 1, 2009.
`Choi Y, He B, Neelarapu R, Velaparthi S, Blond S, Petukhov PA, van Breemen RB. HDAC3
`and HDAC8 alkylation by a selective photoaffinity labeling inhibitor. 58th ASMS Conference on
`Mass Spectrometry and Allied Topics. Salt Lake City, UT. May 23-27, 2010.
`Song Y, van Breemen RB, Franzblau SG. Applications of HepaRG cells for cytotoxicity and
`cytochrome P450 induction studies. 58th ASMS Conference on Mass Spectrometry and Allied
`Topics. Salt Lake City, UT. May 23-27, 2010.
`Chen L, Li J, Cushman M, Pezzuto JM, van Breemen RB. In vitro hepatic metabolism of 3-
`amino-6-(3-aminopropyl)-5,6-dihydro-5, 11-dioxo-11H-indeno[1,2-c] isoquinoline
`dihydrochloride, a promising cancer chemoprevention agent. 58th ASMS Conference on Mass
`Spectrometry and Allied Topics. Salt Lake City, UT. May 23-27, 2010.
`Dong L, Shion HY, Davis R, Terry-Penak B, van Breemen RB. Collision cross-section
`determination of isomeric carotenoids using electrospray ion mobility time-of-flight mass
`spectrometry. 58th ASMS Conference on Mass Spectrometry and Allied Topics. Salt Lake City,
`UT. May 23-27, 2010.
`Nikolic D, Li J, Gödecke T, Chen S-N, Pauli GF, van Breemen RB. Mass spectrometric
`identification and characterization of cytochrome P4502D6 inhibitors from black cohosh (Actaea
`racemosa L.). 58th ASMS Conference on Mass Spectrometry and Allied Topics. Salt Lake City,
`UT. May 23-27, 2010.
`Wright B, Mo S, Dong L, Hurst WJ, van Breemen RB. Pharmacokinetics of epicatechin in
`humans after ingestion of cocoa products. 58th ASMS Conference on Mass Spectrometry and
`Allied Topics. Salt Lake City, UT. May 23-27, 2010.
`Li J, Cushman M, Pezzuto JM, van Breemen RB. LC-MS-MS determination of zapotin from
`Casimiroa edulis in rat serum and tissues. 58th ASMS Conference on Mass Spectrometry and
`Allied Topics. Salt Lake City, UT. May 23-27, 2010.
`Ahn S, Powell SL, Gödecke T, Pauli GF, Bolton JL, van Breemen RB. Studies of intestinal
`absorption, BBB penetration and rat serum levels of N-methylseorotonin. 58th ASMS Conference
`on Mass Spectrometry and Allied Topics. Salt Lake City, UT. May 23-27, 2010.
`
`
`
`
`
`
`69
`
`
`
`00000101
`
`

`
`April 2012
`
`Yu R, Xiao L, Christman JW, van Breemen RB. Quantitative analysis of prostaglandin (PG)H2
`and its metabolic derivatives using LC-MS-MS. 58th ASMS Conference on Mass Spectrometry
`and Allied Topics. Salt Lake City, UT. May 23-27, 2010.
`White J, van Breemen RB. Development of high-throughput screening pulsed ultrafiltration mass
`spectrometry (HTS-PUF MS). 58th ASMS Conference on Mass Spectrometry and Allied Topics.
`Salt Lake City, UT. May 23-27, 2010.
`Krock K, van Breemen RB. High-throughput mass spectrometry based screening for inhibitors of
`amyloid-β and tau aggregation. 58th ASMS Conference on Mass Spectrometry and Allied
`Topics. Salt Lake City, UT. May 23-27, 2010.
`Li Y, Vaishnav A, Dong L, Nonn L, van Breemen RB. Lycopene sub-cellular localization in
`primary prostate epithelial and stromal cells. 58th ASMS Conference on Mass Spectrometry and
`Allied Topics. Salt Lake City, UT. May 23-27, 2010.
`Qiu X, Yuan Y, Hu C, Vaishnav A, Nonn L, van Breemen RB. Quantitative proteomics of
`lycopene effects on prostate primary epithelial cells by LC-MS/MS. 58th ASMS Conference on
`Mass Spectrometry and Allied Topics. Salt Lake City, UT. May 23-27, 2010.
`Hu C, Nikolic D, Eggler AL, Mesecar AD, van Breemen RB. Screening for natural
`chemoprevention agents that reversibly modify human Keap1. 58th ASMS Conference on Mass
`Spectrometry and Allied Topics. Salt Lake City, UT. May 23-27, 2010.
`Shion H, Nikolic D, Dietz B, Pauli G, Wright B, Hagos G, Lantvit D, Millar A, Shockcor J,
`Twohig M, van Breemen RB. MALDI imaging of distribution of xanthohumol and its
`metabolites in rat tissues. 58th ASMS Conference on Mass Spectrometry and Allied Topics. Salt
`Lake City, UT. May 23-27, 2010.
`Baumgarten S, White J, van Breemen RB. A novel target for pulsed ultrafiltration mass
`spectrometry: vitamin D receptor. 58th ASMS Conference on Mass Spectrometry and Allied
`Topics. Salt Lake City, UT. May 23-27, 2010.
`Mo S, Dong L, Nikolic D, Hurst WJ, van Breemen RB. Identification of cyclooxygenase-2
`inhibitors in cocoa (Theobroma cacao) using ultrafiltration LC-MS. 58th ASMS Conference on
`Mass Spectrometry and Allied Topics. Salt Lake City, UT. May 23-27, 2010.
`Dahl JH, Mo S, Hurst WJ, van Breemen RB. Enhanced workflow for rapid identification of
`ultrafiltration screening ligands. 58th ASMS Conference on Mass Spectrometry and Allied
`Topics. Salt Lake City, UT. May 23-27, 2010.
`Yuan Y, Lum H, Yoder MA, van Breemen RB. Quantitative analysis of lysophosphatidylcholine
`in human bronchoalveolar lavage fluid. 58th ASMS Conference on Mass Spectrometry and
`Allied Topics. Salt Lake City, UT. May 23-27, 2010.
`Al-Alem U, Gann PH, Dahl J, van Breemen R, Van Horn L, Wright ME. Functional
`polymorphisms in endogenous antioxidant defense genes and oxidative stress levels in women: a
`genotype-phenotype study. American Association for Cancer Research (AACR) 102nd Annual
`Meeting. Orlando, FL. April 2-6, 2011.
`Li Y, van Breemen RB, Min Chang. Suppression of analyte ionization during electrospray LC-
`MS-MS by plasma matrix phospholipids. 59th Annual Conference on Mass Spectrometry and
`Allied Topics. Denver, CO. June 5-9, 2011.
`
`
`
`
`
`
`70
`
`
`
`00000102
`
`

`
`April 2012
`
`White J, Cushman M, van Breemen RB. Discovery and lead structure optimization of a non-
`secosteroid binding partner for the vitamin D receptor. 59th Annual Conference on Mass
`Spectrometry and Allied Topics. Denver, CO. June 5-9, 2011.
`Dong L, Shion H, Davis R, van Breemen RB. Analysis of cis/trans isomers of carotenoids using
`ion mobility time-of-flight mass spectrometry. 59th Annual Conference on Mass Spectrometry
`and Allied Topics. Denver, CO. June 5-9, 2011.
`Mo S, Dong L, Hurst WJ, van Breemen RB. Quantitative analysis of phytosterols in cocoa and
`vegetable oils using liquid chromatography-tandem mass spectrometry. 59th Annual Conference
`on Mass Spectrometry and Allied Topics. Denver, CO. June 5-9, 2011.
`Yuan Y, Qiu X, Yang Y, van Breemen RB. Quantitative analysis of bisphenol A in rat serum by
`LC-MS-MS. 59th Annual Conference on Mass Spectrometry and Allied Topics. Denver, CO.
`June 5-9, 2011.
`Song Y, Peng K, Zhang N, van Breemen RB, Franzblau SG. Simultaneous measurement of
`fifteen anti-tuberculosis compounds using LC-MS-MS. 59th Annual Conference on Mass
`Spectrometry and Allied Topics. Denver, CO. June 5-9, 2011.
`Dahl JH, van Breemen RB. Identification of in vitro lycopene metabolites using isotope pattern
`dependent MS-MS. 59th Annual Conference on Mass Spectrometry and Allied Topics. Denver,
`CO. June 5-9, 2011.
`Qiu X, Yuan Y, van Breemen RB. Use of LC-MS-MS to assess induction of human CYP1A2
`and CYP3A4 by hops. 59th Annual Conference on Mass Spectrometry and Allied Topics.
`Denver, CO. June 5-9, 2011.
`Chen K, Conda-Sheridan M, Cushman M, Pezzuto JM, van Breemen RB. Human metabolism of
`AM6-36, a retinoid X receptor-alpha ligand. 59th Annual Conference on Mass Spectrometry and
`Allied Topics. Denver, CO. June 5-9, 2011.
`Yuan Y, Nikolic D, Wright B, Dahl JH, van Breemen RB. Quantitative analysis of hop
`prenylflavonoids in human serum using UHPLC-MS-MS. 59th Annual Conference on Mass
`Spectrometry and Allied Topics. Denver, CO. June 5-9, 2011.
`Baumgarten S, Omene BO, Gaba RC, van Breemen RB. Confirmation of drug delivery after
`liver chemoembolization: direct tissue doxorubicin measurement by LC-MS-MS. 59th Annual
`Conference on Mass Spectrometry and Allied Topics. Denver, CO. June 5-9, 2011.
`Sun Z, Hu C, Pituch K, Lopez-Rosas A, van Breemen RB, Givogri MI. Quantitative analysis of
`sulfatides in neurological specimens using LC-MS-MS. 59th Annual Conference on Mass
`Spectrometry and Allied Topics. Denver, CO. June 5-9, 2011.
`Huang K, Liu G, White JJ, van Breemen RB. Discovery of natural product ligands of human
`RAR-gamma using ultrafiltration UHPLC-MS-MS; 59th Annual Conference on Mass
`Spectrometry and Allied Topics. Denver, CO. June 5-9, 2011.
`Wright B, Mo S, Dong L, Dahl J, Hurst WJ, van Breemen RB. Quantitative analysis of
`epicatechin metabolites in human serum using UHPLC-MS-MS. 59th Annual Conference on
`Mass Spectrometry and Allied Topics. Denver, CO. June 5-9, 2011.
`Nikolic D, Yuan Y, Wright B, BanuvarS, Shulman L, van Breemen RB. LC-MS analysis of
`prenylated flavonoids from hops in support of a Phase I clinical trial. 59th Annual Conference on
`Mass Spectrometry and Allied Topics. Denver, CO. June 5-9, 2011.
`
`
`
`
`
`
`71
`
`
`
`00000103
`
`

`
`April 2012
`
`Newsome A, Tanouye U, Baumgarten S, Wei X, Murphy M, van Breemen RB. Comparison of
`secondary metabolite profiles of a marine actinomycete cultured in the presence and absence of
`agar by LCMS-IT-TOF. 59th Annual Conference on Mass Spectrometry and Allied Topics.
`Denver, CO. June 5-9, 2011.
`Krock K, van Breemen RB. High throughput UHPLC-mass spectrometry based screening for
`inhibitors of microtubule associated protein tau aggregation. 59th Annual Conference on Mass
`Spectrometry and Allied Topics. Denver, CO. June 5-9, 2011.
`Pezzuto JM, Cushman M, Fenical W, Mesecar A, van Breemen RB. The role of natural products
`in cancer chemoprevention. 2nd Annual Conference of the American Council for Medicinally
`Active Plants. Huntsville, AL. July 17-20, 2011.
`van Breemen RB, Abou-Nemeh I. Proposal for the 2014 International Carotenoid Conference in
`Chicago, IL. 16th International Symposium on Carotenoids. Krakow, Poland. July 17-21, 2011.
`Abdelkarim H, Brunsteiner M, He B, Neelarapu R, Choi YS, van Breemen RB, Petukhov PA.
`Mapping the binding sites of HDAC3/NCoR2 complex using photoreactive chemical probes. 9th
`Annual Chicago Biomedical Consortium Symposium. Chicago, IL. October 21, 2011.
`Pezzuto JM, Cushman MS, Fenical W, Mesecar A, van Breemen RB. The challenges and
`promise of cancer chemoprevention: The role of natural products. 3rd Brazilian Conference on
`Natural Products (BCNP). Ouro Preto, MG, Brazil. October 29-November, 2011.
`Huang K, Ahn S, Dahl JH, van Breemen RB. Detection of reactive metabolites by glutathione
`trapping and UHPLC-MS-MS with fast precursor ion and neutral loss scanning. The Association
`for Mass Spectrometry: Applications to the Clinical Lab MSACL 2012. San Diego, CA. January
`14-18, 2012.
`Abdelkarim H, Brunsteiner M, He B, Neelarapu R, Choi YS, van Breemen RB, Petukhov PA.
`The development and implementation of chemical nanites to probe the HDAC3/NCoR2
`interface. 1st Annual Conference of the Society for Laboratory Automation and Screening
`(SLAS). San Diego, CA. February 2-8, 2012.
`Abdelkarim H, Brunsteiner M, He B, Neelarapu R, Choi YS, van Breemen RB, Petukhov PA.
`Implementation of photoreactive chemical probes in characterizing HDAC3/NCoR complex: a
`step toward neurodegenerative compatible HDAC inhibitors. 6th Drug Discovery for
`Neurodegeneration Conference. New York, NY. February 12-14, 2012.
`
`
`
`
`72
`
`
`
`
`
`
`
`00000104
`
`

`
`April 2012
`
`EXTERNAL RESEARCH SUPPORT
`
`Richard B. van Breemen
`
`University of Illinois College of Pharmacy
`Department of Medicinal Chemistry and Pharmacognosy
`
`
`1. Past
`
`01-24-86 to 01-23-89
`$600,000
`
`North Carolina Biotechnology Center
`"Development of a mass spectrometry laboratory
`for biotechnology research"
`Co-P.I. (Sims, L.B. and Armstrong, F.B.)
`
`04-01-86 to 03-31-87
`NIH Biomedical Research Support Grant
`$11,500
`BRSG No. RR7071
`"Analysis of alkylated enzymes and proteins by HPLC and mass spectrometry"
`Principal Investigator
`
`05-01-86 to 04-30-87
`North Carolina Biotechnology Center
`"Development of analytical methods for analysis of $22,570
`covalent modifications of proteins"
`Principal Investigator
`
`Faculty Research & Professional Development Award 01-01-88 to 12-31-88
`Grant No. 01042
`$3,500
`"Analysis of substituted transition metal carbonyls by mass spectrometry"
`Principal Investigator
`
`06-01-88 to 05-31-89
`North Carolina Biotechnology Center
`$18,026
`"Immobilization of bacterial enzymes involved in
`the environmental degradation of organic chemical pollutants."
`Principal Investigator
`
`05-15-89 to 04-30-90
`Physical and Mathematical Sciences Foundation
`$1,500
`Dean's Fund
`"Degradation of pollutants using immobilized enzymes"
`Principal Investigator
`
`06-01-89 to 07-31-91
`Petroleum Research Fund
`$18,000
`ACS-PRF #21692-G7
`"Oxygenation of petrochemicals by immobilized bacterial enzymes"
`Principal Investigator
`
`02-01-90 to 01-31-91
`Glaxo, Inc.
`$5,000
`"Use of immobilized proteases and liquid
`chromatography-mass spectrometry to identify hydrolysis products of peptide-analog drugs"
`Principal Investigator
`
`
`
`
`
`
`73
`
`
`
`
`
`00000105
`
`

`
`April 2012
`
`04-01-92 to 03-31-93
`$2,500
`
`06-01-91 to 12-31-91
`$45,476
`
`03-15-92 to 08-31-94
`$40,000
`
`Glaxo, Inc.
`"Sites of protein-RNA crosslinking determined
`by liquid chromatography-mass spectrometry"
`Principal Investigator
`
`ABB Transmission & Technology Institute
`"Analysis of transformer oil samples for
`paper degradation products"
`Principal Investigator
`
`06-01-91 to 05-31-93
`Southeast Dairy Foods Research Center
`$96,520
`"Supercritical fluid fractionation of dairy lipids:
`compositional and structural characterization of isolated triglycerides"
`Co-Investigator (P.I. Schwartz, S.J.)
`
`United States Department of Agriculture
`"Analysis of carotenoids and retinoids by
`liquid chromatography-mass spectrometry"
`Co-Principal Investigator (co-P.I. Schwartz, S.J.)
`
`National Science Foundation, BIR-9111391
`"Acquisition of a data system for a liquid
`chromatograph-mass spectrometer"
`Principal Investigator
`
`ISIS Pharmaceuticals
`"Identification and quantitation of antisense
`therapeutic agents in biological fluids"
`Principal Investigator
`
`Genentech, Inc.
`"Hydrolysis of peptide and protein drugs using
`immobilized hepatic proteases”
`Principal Investigator
`
`12-15-92 to 11-30-95
`National Science Foundation
`$210,000
`BIR-9204042
`"Quantifying adsorption of peptides at gas-liquid interfaces"
`Principal Investigator
`
`09-30-94 to 09-29-95
`Department of Health and Human Services
`$263,467 (total)
`H75/ATH598336-02
`"Great Lakes fish as a source of maternal and fetal exposure to chlorinated hydrocarbons”
`Co-Investigator (P.I. Waller, D.)
`
`National Institutes of Health/Northwestern University 08-05-95 to 08-04-97
`"Low-Fat High-Fiber Soy Rich Diet in
`$155,312 (direct costs), $229,551 (total)
`Premenopausal Women"
`
`Co-Principal Investigator (co-P.I. Beecher, C.W.)
`74
`
`
`08-01-92 to 07-31-94
`$60,193
`
`04-01-92 to 03-31-93
`$36,618
`
`05-01-92 to 04-10-93
`$10,000
`
`
`
`
`
`
`00000106
`
`

`
`12-15-95 to 12-31-96
`UIC Campus Research Board
`$14,000
`F95-115
`“Metabolism of antisense drugs: analysis using affinity LC/MS”
`Principal Investigator
`
`April 2012
`
`07-01-96 to 06-30-97
`$209,104
`
`07-01-96 to 05-31-98
`$217,550
`
`01-01-97 to 12-31-97
`$9,000
`
`
`
`National Institutes of Health
`1 S10RR10485
`“Acquisition of an electrospray mass spectrometer”
`Principal Investigator
`
`05-01-96 to 04-30-98
`National Science Foundation
`$90,000
`BIR-9513204
`“Acquisition of electrospray LC-MS and LC-MS-MS instrumentation”
`Principal Investigator
`
`11-01-96 to 04-30-97
`Functional Foods for Health Program
`$10,000
`University of Illinois
`“Stable isotope-labeled nucleosides for LC-MS quantitation DNA oxidation products”
`Co-Principal Investigator (co-P.I. Bowen, P.E.)
`
`10-1-96 to 12-31-96
`Pharmacia & Upjohn
`“Screening combinatorial libraries and quantification $10,460 (direct) $18,090 (total)
`of ligand-receptor interactions using pulsed ultrafiltration
`(PUF)/electrospray mass spectrometry”
`Principal Investigator
`
`Hewlett-Packard Company
`“Liquid chromatograph-electrospray mass
`spectrometer for screening molecular diversity”
`Principal Investigator
`
`12-01-97 to 05-31-99
`
`Hunt-Wesson
`“Effect of tomato sauce on DNA oxidation in prostate” $4,718 (direct RvB) $5,898 (total RvB)
`Co-Investigator (P.I. Bowen, P.E.)
`
`UIC Campus Research Board
`2-6-42225
`“Development of LC-MS assay for DNA oxidation”
`Co-Principal Investigator (co-P.I. Bolton, J.L.)
`
`06-15-97 to 06-14-98
`Pharmacia & Upjohn
`$14,000
`“Determination of serum albumin binding of drugs
`and screening for active metabolites in biological fluids”
`Principal Investigator
`
`Monsanto Company
`“Screening for inhibitors of cyclooxygenase
`using pulsed ultrafiltration mass spectrometry”
`Principal Investigator
`
`
`12-01-97 to 11-30-98
`$10,000
`
`75
`
`
`
`
`
`
`00000107
`
`

`
`April 2012
`
`
`
`
`
`
`
`
`12-1-97 to 11-30-98
`Functional Foods for Health Program
`$10,000
`University of Illinois
`“Mechanism of chemoprotection by dietary phenols”
`Co-Principal Investigator (co-P.I. Bolton, J.L.)
`
`04-15-97 to 02-28-02
`National Institutes of Health
`$585,497 (direct) $899,369 (total costs)
`R01 CA70771
`
`“Prevention of DNA Oxidation by Tocopherol and Carotenoids”
`Principal Investigator
`
`05-01-98 to 01-31-99
`Hewlett-Packard Company
`“Evaluation of pulsed ultrafiltration-mass spectrometry” $180,000
`Principal Investigator
`
`07-01-98 to 6-30-04
`National Institutes of Health
`$947,987 (direct) $4,820,250 (total)
`P01 CA48112
`“Natural inhibitors of carcinogenesis” $83,210 (direct, year 1; RvB) $329,044 (total; RvB)
`Core Leader (P.I. Pezzuto, J.M.)
`
`09-09-98 to 11-15-98
`Monsanto – Agracetus
`“Analysis of Salicornia bigelovii Seed Oil and Meal” $19,667
`Co-Investigator (P.I. Fitzloff, J.)
`
`09-30-98 to 09-30-02
`National Cancer Institute
`$166,480 (direct) $259,492 (total)
`N01-CN-15017-44 (Workstatement 85)
`“Screening chemopreventive agents in the N-butyl-N-(4-hydroxybutyl)-nitrosamine [OH BBN]
`model of bladder carcinogenesis”
`Co-Investigator (P.I. Pezzuto, J.M.)
`
`09-30-98 to 09-30-02
`National Cancer Institute
`$266,385 (direct) $413,696 (total) ($24,100 RvB)
`NCI Workstatement No. 83
`“Chemoprevention of induced mammary tumors in the rat by combination of chemopreventive
`agents”
`Co-Investigator (P.I. Pezzuto, J.M.)
`
`9-30-98 to 9-30-03
`National Institutes of Health
`$1,012,595 (direct) $1,503,775 (total)
`NO1 CN85081-70
`“Phase I single and multiple-dose safety and pharmacokinetic study of lycopene in men”
`Co-Investigator (P.I. Gustin, D.)
`
`07-01-99 to 06-30-04
`National Institutes of Health
`$650,000 (direct) $1,051,321 (total)
`R24 CA83124
`
`“Core mass spectrometry resource for cancer research”
`Principal Investigator
`
`National Institutes of Health
`P50 AT00155
`
` “Botanical dietary supplements for women’s health”
`76
`
`
`09-01-99 to 07-31-04
`$5,127,273 (direct) $7,945,707 (total)
`
`
`
`
`
`
`00000108
`
`

`
`April 2012
`
`Co-Director, Project Leader, Core Leader
`
`01-8-99 to 11-30-02
`National Institutes of Health
`$533,521 (direct) $859,975 (total)
`R01 CA79870
`“Carcinogenic metabolites formed from antiestrogens”
`Co-Investigator (P.I. Bolton, J.L.)
`
`05-08-00 to 01-14-03
`National Cancer Institute
`$331,991 (direct) $482,937 (total)
`N01-CM-87103
`“Pharmacokinetic and toxicity studies for betulinic acid (NSC-113090)”
`Co-Investigator (P.I. Levine, B.)
`
`
`
`09-30-00 to 09-29-02
`National Cancer Institute
`$155,155 (direct) $240,956 (total)
`N01-CN-05024-40, NCI Workstatement 79
`“Chemoprevention screening employing a transgenic mouse model which yields prostate tumors in
`male mice and breast tumors in female mice”
`Co-Investigator (P.I. Pezzuto, J.M.)
`
`10-01-00 to 09-30-02
`National Foundation for Cancer Research
`“Lycopene modulation of prostate tissue DNA damage, cell death and proliferation in men with
`prostate cancer”
`
`$253,338 (direct) $291,339 (total costs)
`Co-investigator (P.I. Bowen, P.E.)
`
`09-30-00 to 09-29-02
`National Cancer Institute
`$112,726 (direct) $175,064 (total)
`N01-CN-05024-40 (Workstatement 73)
`“Screening of chemopreventive agents in the MNU-induced rat mammary tumor model”
`Co-Investigator (P.I. Pezzuto, J.M.)
`
`National Institutes of Health
`1 M01 RR13987
` “General Clinical Research Center”
`Co-Investigator (P.I. Moss, G.S.);
`This grant supported the General Clinical Research Center at UIC and Dr. van Breemen’s R01-
`supported lycopene clinical trials.
`
`ACS Corporation Associates Grants
`ACS Symposium
`
`“Analytical Tools for Combinatorial Chemistry”
`Principal Investigator (Co-Chair: Buko, A.)
`
`04-01-01 to 03-31-02
`National Institutes of Health
`$276,050 (direct)
`1 S10 RR14686
`“Matrix-assisted Laser Desorption TOF Mass Spectrometer”
`Principal Investigator
`
`07-01-01 to 06-30-03
`UIC Campus Research Board
`“Synthesis and screening of serotonin antagonists” $77,000 (direct costs only)
`Co-investigator (P.I. Carley, D.)
`
`
`
`12-1-00 to 11-30-05
`$9,176,703 (total)
`
`
`
`08-29-01 to 08-30-01
`$2,000
`
`
`
`
`77
`
`
`
`00000109
`
`

`
`April 2012
`
`04-01-01 to 03-31-06
`National Institutes of Health
`$1,250,000 (direct) $1,816,340 (total)
`R01 CA73638
`“Biotransformation of estrogens to carcinogenic quinoids”
`Co-investigator (P.I. Bolton, J.L.)
`
`
`
`08-01-01 to 07-31-04
`National Institutes of Health
`$965,806 (direct) $1,320,666 (total)
`5R01 CA096517
`“Mechanism(s) of antitumor action of tamoxifen and soy”
`Co-Investigator (P.I. Constantinou, A.)
`
`09-30-01 to 03-29-04
`National Cancer Institute (Workstatement 80)
`$205,250 (direct) $319,923 (total)
`N01-CN-15017-44
`“Screening various chemopreventive agents in MNU-induced rat mammary tissues”
`Co-Investigator (P.I. Pezzuto, J.M.)
`
`09-01-02 to 08-31-08
`National Institutes of Health/NCI
`$292,224
`7 R01CA90759
`“The effects of lycopene on high-risk prostatic tissue”
`Co-investigator (P.I. Gann, P)
`
`
`
`09-01-02 to 12-31-09
`National Institutes of Health
`$1,050,000 (direct) $1,583,734 (total)
`R01 CA79870
`“Carcinogenic metabolites formed from antiestrogens”
`
`
`
`
`Co-investigator (P.I. Bolton, J.L.)
`
`National Institutes of Health
`1 R21 AI052847
`“The metabolome of non-replicating M. tuberculosis”
`Co-Investigator (P.I. Pauli, G.F.)
`
`12-1-02 to 11-30-07
`National Institutes of Health
`$2,474,005 (direct) $2,662,490 (total)
`2 R25 CA057699
`“Cancer education and career development program”
`Co-investigator (P.I. Warnecke, R.B.)
`
`UIC/NIH Botanical Center Pilot Project Program
`“Oral lycopene in cervical dysplasia”
`Principal Investigator
`
`09-30-02 to 08-31-04
`$300,000 (direct) $467,610 (total)
`
`04-01-03 to 3-31-04
`$46,001 (direct) $77,650 (total)
`
`07-01-03 to 06-30-05
`$100,000 (direct) $148,930 (total)
`
`05-01-03 to 04-30-10
`National Institutes of Health
`$1,250,000 (direct) $1,676,472 (total)
`1 R01 CA101052
`“Mechanisms of prostate cancer prevention by lycopene”
`
`
`
`Principal Investigator
`
`National Institutes of Health
`1 R03 CA103310-01
` “The bioavailability of folate in humans”
`Principal Investigator
`
`
`
`
`
`
`78
`
`
`
`00000110
`
`

`
`April 2012
`
`07-01-04 to 04-30-05
`$29,524 (direct RvB) $51,569 (total RvB)
`
`National Institutes of Health
`P01 CA48112 supplement
`“Natural inhibitors of carcinogenesis”
`Core Leader (P.I. Pezzuto, J.M.)
`Supplement to program project grant as bridge funding between 5 year funding cycles
`
`National Institutes of Health
`P50 AT00155 supplement
`“Botanical dietary supplements for women’s health”
`Co-Director, Project Leader, Core Leader
`
`09-01-04 to 03-31-05
`$1,013,660 (total)
`
`
`
`National Institutes of Health
`1 R01 CA102590
`“Biointeractions of antiestrogens with NO”
`Co-investigator (P.I. Thatcher, G.R.)
`
`01-15-05 to 12-31-09
`$158,000 (annual direct costs)
`
`
`04-01-05 to 03-31-07
`National Institutes of Health
`$383,000 (annual direct costs)
`1 S10 RR019370-01A1
`“2D-HPLC-tandem mass spectrometer for proteomics”
`Principal Investigator
`
`National Institutes of Health
`P50 AT00155 (years 5-10)
`“Botanical dietary supplements for women’s health”
`Co-director, Project Leader, Core Leader (P.I. Farnsworth, N.R.)
`
`04-01-05 to 6-30-10
`$3,415,860 (direct) $5,333,333 (total)
`
`4-01-05 to 3-31-10
`National Institutes of Health
`$250,000 (annual direct costs)
`2R01HL063774
`“Dynamic interactions of cardiac troponin and tropomyosin”
`Co-Investigator (P.I. Tobacman, L.)
`
`
`
`National Institutes of Health
`2 P01 H62426-06
`“Integrated mechanisms of cardiac maladaption”
`Co-investigator Core C (P.I. Solaro/Tomoyoshi)
`
`04-01-05 to 05-31-10
`$241,802 (RvB)
`
`
`
`
`09-01-06 to 8-32-07
`$57,660 (total)
`
`National Institutes of Health
`5P01 AT002605
`“Arthritis and traditional Chinese medicine”
`Co-investigator (P.I. Berman, B., University of Maryland)
`
`09-20-06 to 08-31-08
`National Institutes of Health/NIAID
`$232,500
`1 R21 AI067652
`“Lead identification of 1, 4-benzoxazines as anti-tuberculosis agents”
`Co-investigator (P.I. Franzblau, S)
`
`04-01-07 to 06-30-09
`Shimadzu Scientific Instruments
`“High performance LC-MS-MS for natural products analysis” $128,500
`Principal Investigator
`
`
`
`
`
`
`79
`
`
`
`00000111
`
`

`
`April 2012
`
`04-01-07 to 03-31-09
`National Institutes of Health
`$289,904 (direct costs only)
`1 S10 RR023785
`“HPLC time-of-flight mass spectrometer for accurate mass measurements”
`Principal Investigator
`
`
`06-01-07 to 5-31-08
`Thermo Fisher Scientific
`“Ion trap LC-MSn for ultrafiltration mass spectrometry” $300,000
`Principal Investigator
`
`05-07-09 to 05-06-10
`National Institutes of Health
`$127,751
`1S10RR024669
`“A shared FTMS instrument upgrade to further biomolecular research”
`Co-investigator (P.I. Schilling, A.)
`
`
`
`2. Present
`
`08-01-09 to 07-31-11
`$196,554 (total costs; RvB)
`
`09-01-10 to 08-31-15
`P50 AT00155 (years 11-15)
`$4,787,594 (direct) $7,420,771 (total)
`National Institutes of Health
`“Botanical Dietary Supplements for Women’s Health”
`Principal Investigator, Director, Project Leader, Core Leader
`This is the second competitive renewal of this NIH Center grant for Dietary Supplements
`Research which is focused on the safety, efficacy and mechanism of action of botanicals used to
`treat menopause and PMS.
`
`09-01-11 to 08-31-12
`P50 AT0015511S1
`$94,328 (direct) $141,208 (total)
`National Institutes of Health
`“Single Laboratory Validation of Analytical Methods for Estrogenic Botanical Constitutents”
`Principal Investigator
`This administrative supplement of the Botanical Center P50 grant is supporting the development
`and validation of UHPLC-MS-MS assays for the quantitative analysis of active constituents of
`botanical dietary supplements.
`
`
`P01 CA48112
`National Institutes of Health/NCI
`“Natural Inhibitors of Carcinogenesis”
`Project Leader (P.I. Pezzuto, JM)
`Within this program project searching for chemopreventive agents from natural products sources
`using bioassay-guided fractionation, Prof. van Breemen directs a project entitled, “Mass
`spectrometry-based discovery,” that supports the screening and identification of natural product
`lead compounds. This grant was renewed for another five years beginning in 2005.
`
`P01 CA048112-17S1
`National Institutes of Health/NCI
`“Natural Inhibitors of Carcinogenesis”
`American Recovery and Reinvestment Act of 2009 Administrative Supplement
`Dr. van Breemen is using this administrative supplement to enhance the productivity of his mass
`spectrometry-based drug discovery and development effort in the area of cancer
`chemoprevention by natural products.
`
`
`04-01-06 to 03-31-12
`$119,000 (annual direct costs; RvB)
`
`
`
`
`80
`
`
`
`00000112
`
`

`
`April 2012
`
`
`
`
`
`
`
`10-01-09 to 05-30-14
`2R01 CA79870
`$1,149,545
`National Institutes of Health/NCI
`“Carcinogenic metabolites formed from antiestrogens”
`
`Co-investigator (P.I. Bolton, J.L.)
`Dr. van Breemen is applying LC-MS-MS to the quantitative analysis of oxidized nucleosides as
`a measure of DNA damage by metabolites of antiestrogens. He is also screening metabolites for
`binding to the estrogen receptors and using LC-MS-MS to determine the structures of
`antiestrogen metabolites.
`
`08-31-07 to 5-31-12
`5R01CA130037
`$291,366 (annual) $1,445,830 (total)
`National Institutes of Health/NCI
`“Role of electrophilic/redox active quinoids in estrogen carcinogenesis”
`Co-investigator (P.I. Bolton, JL)
`Prof. van Breemen is using quantitative and qualitative LC-MS-MS to characterize oxidized
`nucleosides and nucleoside adducts formed by reaction of DNA with estrogen metabolites.
`
`12-01-08 to 11-30-13
`
`
`
`
`1R01CA129140
`$2,248,733 (direct) $3,073,209 (total)
`
`
`National Institutes of Health/NCI
`“Adiposity of outcomes of clinically localized prostate cancer”
`Co-investigator (P.I. Freeman, V)
`Prof. van Breemen is using quantitative LC-MS-MS assays to evaluate biochemical markers
`including eicosanoid products of arachidonic acid and metabolites of estrogen and testosterone to
`clarify the mechanistic basis for the association of excessive adiposity and prostate cancer
`progression.
`
`07-01-08 to 06-30-12
`
`
`
`
`1R01CA131970
`$830,000 (direct) $1,271,200 (total)
`
`
`National Institutes of Health/NCE
`“Photoaffinity labeling probes for development of novel isoform selective HDAC inhibitors for
`cancer”
`Co-investigator (P.I. Petukhov, P)
`Prof. van Breemen’s role in this project is to identify the sites of binding of HDAC inhibitors
`using affinity labeling and proteomics mass spectrometry. These measurements will demonstrate
`the selectivity of binding and inhibition of novel synthetic HDAC inhibitors.
`
` 5
`
`09-30-05 to 08-31-11
`$34,861 (direct UIC)
`
`
`
`
`
` P01 AT002605-05
`
`National Institutes of Health/NCCAM
`“Arthritis and Traditional Chinese Medicine”
`Co-investigator (P.I. Berman, B.; University of Maryland)
`The objective of this multidisciplinary program project concerns the establishment of a Center
`for research in complementary and alternative medicine that is focused on arthritis and
`traditional Chinese medicine (TCM). Prof. van Breemen’s role has been the screening of Chinese
`medicinal plants for the identification of cyclooxygenase-2 inhibitors.
`
`05-31-06 to 12-31-12
`Hershey Foundation
`$402,082 (direct) $558,000 (total)
`Principal Investigator
`“Analysis of cacao, cocoa powder and chocolate for bioactive compounds.” Chocolate products
`will be assayed for antioxidants using LC-MS and LC-MS-MS.
`
`National Institutes of Health/NCI
`
`
`
`
`
`04-09-09 to 03-08-12
`
`81
`
`
`
`00000113
`
`

`
`April 2012
`
`$438,118 (direct) $687,845 (total)
`1R21CA131787
`“Retinoid and carotenoid depletion in patients at high-risk for liver cancer”
`Co-investigator (P.I. Gann, P.)
`Prof. van Breemen’s role in this project is to carry out the quantitative analysis of carotenoids
`and retinoids in serum and liver tissue samples. He will also be responsible for the measurement
`of biomarkers of oxidative stress in urine such as 8-oxo-deoxyguanosine and prostanoids.
`
`09-04-09 to 08-31-12
`National Institutes of Health/NCI
`$139,528
`1R21CA131787-02, ARRA
`“Retinoid and carotenoid depletion in patients at high-risk for liver cancer”
`Co-investigator (P.I. Gann, P.)
`This project is part of an effort to find safe and effective ways to prevent liver cancer.
`Specifically, correcting deficiencies in two important classes of dietary antioxidants will be
`evaluated including retinoids (vitamin A) and carotenoids (β-carotene and lycopene).
`
`07-01-10 to 07-01-12
`Society of Interventional Radiology
`$100,000 ($24,605 RvB)
`2010-06074
`“Confirmation of drug delivery after chemembolization: Direct doxorubicin measurement and
`correlation with CT calculated ethiodol concentration”
`Co-investigator (P.I. Gaba, R.)
`Prof. van Breemen is using LC-MS-MS to measure concentrations of the chemotherapeutic agent
`doxorubicin in liver tiss